The blockade of CTLA4 and PD-1/PD-L1 has revolutionized treatment of highly immunogenic tumors such as melanoma and NSCLC21,22 but, so far, results in BC have been restricted to basal-like tumors in combination with radiotherapy or chemotherapy23. This evidence concerns the gene CTLA4 and melanoma.